Application | Comment | Organism |
---|---|---|
medicine | angiotensin-converting enzyme 2 (ACE2) fused to the Fc portion of immunoglobulin neutralizes SARS-CoV-2 in vitro. Provision of soluble recombinant human ACE2 protein can be beneficial as a novel biologic therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. If given in its soluble form as an appropriate recombinant ACE2 protein, a new tool may be at hand to combat the spread of coronavirus in susceptible individuals by limiting coronavirus attachment to the cell membranes, cell entry, and replication | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
plasma membrane | the full-length enzyme (ACE2) contains a structural transmembrane domain, which anchors its extracellular domain to the plasma membrane | Homo sapiens | 5886 | - |
soluble | the soluble form of angiotensin-converting enzyme 2 lacks the membrane anchor and circulates in small amounts in the blood | Homo sapiens | - |
- |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q9BYF1 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
alveolar cell | expression in type 2 pneumocytes | Homo sapiens | - |
blood | the soluble form of angiotensin-converting enzyme 2 lacks the membrane anchor and circulates in small amounts in the blood | Homo sapiens | - |
gastrointestinal tract | - |
Homo sapiens | - |
kidney | - |
Homo sapiens | - |
lung | low level of expression. RNA expression of angiotensin-converting enzyme 2 (ACE2) in lung AT2 cells was higher in one Asian donor as compared with white and African American donors | Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
ACE2 | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
drug target | angiotensin-converting enzyme 2 (ACE2) fused to the Fc portion of immunoglobulin neutralizes SARS-CoV-2 in vitro. Provision of soluble recombinant human ACE2 protein can be beneficial as a novel biologic therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. If given in its soluble form as an appropriate recombinant ACE2 protein, a new tool may be at hand to combat the spread of coronavirus in susceptible individuals by limiting coronavirus attachment to the cell membranes, cell entry, and replication | Homo sapiens |
physiological function | the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. Functionally, there are two forms of ACE2. The full-length ACE2 contains a structural transmembrane domain, which anchors its extracellular domain to the plasma membrane. The extracellular domain is a receptor for the spike (S) protein of SARS-CoV, and for the SARS-CoV-2. The soluble form of ACE2 lacks the membrane anchor and circulates in small amounts in the blood. It is proposed that this soluble form may act as a competitive interceptor of SARS-CoV and other coronaviruses by preventing binding of the viral particle to the surface-bound, full-length ACE2 | Homo sapiens |